With the above findings, we concluded that this group of patients with type 2 diabetes mellitus and CKD are adults over 70 years of age, who mostly also suffer from arterial hypertension and are treated mainly with metformin alone or combined with DPP4 inhibitors and insulins for their type 2 diabetes mellitus and with ARB or ACEi for their arterial hypertension and as nephroprotective agents, which can provide adequate metabolic and cardiorenal control. The gene discussed is DPP4; the disease is chronic kidney disease.